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Abstract 
Aim: To evaluate the efficacy and safety of donepezil plus natural hirudin in patients with 
mild-to-moderate Alzheimer's Disease. Methods: In the 20-week, randomized, open-label 
and controlled study, 84 patients received either donepezil (5 mg/day for the first 4 weeks and 
10 mg/day thereafter) or donepezil plus natural hirudin (3 g/day) treatment. Efficacy was re-
flected by the change of the total scores of Alzheimer’s Disease Assessment Scale cognitive 
subscale (ADAS-Cog), Activities of Daily Life (ADL) and Neuropsychiatric Inventory (NPI). 
Results: The patients with the donepezil plus natural hirudin treatment showed more sig-
nificant improvement in the daily activities and the decline of the cognition than those with 
donepezil treatment. Significant difference was present in the groups since the 8th week. No 
group difference was found in the NPI change. However, within the hirudin treatment group, 
more powerful efficacy including NPI assessment was found in the patients with vascular risk 
factors (VRF) as comparing to with those without VRF. The combination of donepezil and 
natural hirudin was well tolerated. The dropout rate was greater in the donepezil and natural 
hirudin (50%) treatment group than in the donepezil (39%) treatment group. Similar result 
was found in the incidence of adverse events (23.8% vs 19.0%), but there was no statistical 
difference between the two groups. Adverse events were the most common reason for the 
dropout. Although hemorrhage and hypersensitiveness were more common in donepezil plus 
Maixuekang treatment (11.9% and 7.1%) group than in donepezil treatment (2.4% and 2.4%) 
group, no significant difference was present between the two groups. Economic problem was 
another important reason for the patients’ withdrawal. Conclusions: Compared with the 
donepezil treatment in the patients with mild-to-moderate AD, our results suggest that 
donepezil combined with natural hirudin may improve the treatment effects in the ADL, BPSD 
and cognition of the patients. Furthermore, this joint treatment is safe. 
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Introduction 
Alzheimer’s disease (AD) is characterized clini-
cally  by  a  gradual  decline  in  cognition,  continually 
decreased ability in performing activities of daily liv-
ing  (ADL)  and  finally  increased  behavioural  and 
psychological  symptoms  of  dementia  (BPSD).  At 
present, there is no etiological cure for AD. Available 
treatments mainly offer symptomatic benefit such as 
improving or stabilizing the declined cognition and 
functional and/or behavioral symptoms. The cholin-
esterase inhibitor donepezil has been used to treat the 
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patients with mild to moderately severe AD in many 
countries [1]. The studies using the randomized dou-
ble-blind  placebo-controlled  trials  indicate  that 
donepezil  probably  potentially  benefits  the  patients 
with  mild  to  moderate  AD  in  cognition  [2],  global 
function, and activities of  daily living  [3]. Now the 
combination  of  donapezil  and  other  therapeutic 
strategies like medicamentum alliance is being gener-
ally  studied  in  order  to  get  the  best  treatment  out-
comes.  In  China,  some  traditional  herbal  medicine 
combining choline esterase inhibitors is also studied 
to treat the patients with AD. Thrombosis and ische-
mia are the commonest vascular risk factors and can 
result in the occurrence of AD and aggravated prog-
nosis.  Many  studies  have  shown  that  the  improve-
ment of the cerebral blood supply may be helpful in 
the treatment and rehabilitation of the patients with 
AD.  Typical  anticoagulant  drugs  like  heparin  are 
generally  used  for  the  prevention  and  treatment  of 
thrombotic  disorders.  However,  these  drugs  have 
certain  limitations,  including  variable  anticoagulant 
effect, the potential to cause bleeding, and an inability 
to  inhibit  clot-bound  thrombin  and  thrombocytope-
nia. These limitations have largely restricted its use in 
the treatment of AD. Direct thrombin inhibitors, such 
as hirudin, do not share these limitations. Therefore, 
hirudin, isolated from the salivary gland of the me-
dicinal leech, is a promising agent and probably re-
places heparin in clinic in the future. Natural hirudin 
plays  a  prominent  role  in  blood  rheology  improve-
ment [4] and has been used for many years in China. 
Here we hypothesize that natural hirudin combined 
with donepezil may improve the treatment of AD. No 
report has been published about this combination by 
now. In this prospective study the efficacy and toler-
ance of donepezil combined with natural hirudin will 
be examined on the cognition, ADL and BPSD of the 
patients with mild to moderate AD. 
Methods 
Subjects 
All  patients  enrolled  in  this  study  were  diag-
nosed  as  possible  or  probable  AD  according  to  the 
criteria  of  National  Institute  of  Neurological  and 
Communicative  Disorders  and  Stroke-Alzheimer's 
Disease and Related Disorders Association. Subjects 
with possible cerebrovascular disease such as hyper-
tension and diabetes had to provide eligible evidence 
that these diseases were controlled. Patients who used 
memantine  or  other  cholinesterase  inhibitors  (ri-
vastigmine,  galantamine)  before  but  had  stopped 
them for more than 3 months were also allowed be-
cause 3 months was an adequate washout period for 
those  drugs  based  on  previous  studies  [5].  A 
mini-mental state examination (MMSE) score of 10 - 
26, and a Hachinski score of ≤4 were used to evaluate 
the cognitive impairments needed for the diagnosis of 
AD. Magnetic resonance imaging (MRI) or computed 
tomography was used to confirm a diagnosis of AD. 
Other eligible criteria included normal clinical labor-
atory  values  and  ambulatory  status,  and  sufficient 
vision and hearing for accomplishing testing proce-
dures.  Exclusion  criteria  included:  1)  any  active  or 
clinically significant condition affecting the pharma-
cokinetics of hirudin and donepezil, 2) a known hy-
persensitivity to hirudin or cholinesterase inhibitors, 
3) serious complications of heart, liver or kidney dis-
ease,  4)  any  hematologic  disorders,  5)  any  primary 
psychiatric  disease  other  than  AD,  6)  focal  lesions 
which were detected by CT or MRI and had clinical 
significance, 7) delirium complication, and 8) a known 
or suspected history of alcoholism or drug abuse. 
Study design 
In  this  20-week,  randomized,  open-label,  con-
trolled study, 103 patients were screened and 84 sub-
jects  mentioned  their  intention  to  treat  at  baseline. 
Patients were randomly assigned to either donepezil 
(Brand name: Aricept, Eisai Co. Ltd., Japan) treatment 
or  donepezil  plus  natural  hirudin  (Brand  name: 
Maixuekang,  Guizhou  Xinbang  Pharmaceutical  Co., 
China) treatment. During the administering phase all 
participants took Aricept at a dose of 5 mg/day for 
the  first  4  weeks  and  10  mg/day  thereafter.  In  the 
combination  treatment,  Maixuekang  was  given  at  a 
dose of 3 g/day for the first 16 weeks and the last 4 
weeks was used as its washout period. Patients were 
required to attend a regular interview every 4 weeks 
for  the  following  evaluations:  routine  physical  and 
mental  examination,  ECG  (weeks  8  and  16  only), 
psychometric  tests  (ADAS-Cog,  ADL  and  NPI),  la-
boratory assessments (weeks 8 and 16 only), medica-
tion compliance check, and adverse events monitor-
ing. At the end, 47 completed the trial. This study was 
carried  out  in  accordance  with  the  Declaration  of 
Helsinki.  Written  informed  consents  were  obtained 
from both the patients and the patient’s caregivers.  
Assessing measurements  
The Mini-Mental State Examination (MMSE) is 
widely used to evaluate the cognitive impairments in 
clinical practice and research. In this study, the basal 
cognitive  function  was  evaluated  by  MMSE.  The 
modified Hachinski Ischemic Score was used to detect 
the  vascular  cognitive  impairment  of  AD.  The  Alz-
heimer’s Disease Assessment Scale cognitive subscale 




mains of AD [6, 7]. Total scores ranged from 0-70. The 
higher scores indicated greater cognitive impairment. 
ADL was assessed with a standardized 20-item ADL 
scale. The scores ranged from 0 to 80 and a higher 
score indicated less functional ability. The scores were 
calculated  according  to  the  caregiver’s  description 
about  the  patient  performance  in  the  first  4  weeks. 
The Neuropsychiatric Inventory (NPI) was developed 
to assess the behavioral change in clinical research [8]. 
The standard NPI evaluated 12 neuropsychiatric dis-
turbances common in dementia and was used in this 
study to measure the frequency and severity of be-
havioral psychological symptoms of dementia (BPSD) 
in  the  patients.  The  scores  ranged  from  0  (no  dis-
turbance) to 144 (maximum disturbance).  
Data Analyses 
The  basal  comparison  of  characteristics  in  pa-
tients  with  two  treatments  was  analyzed  by  a  chi 
square test and student’s t test. The efficacy was ana-
lyzed on the base of the changes from baseline to any 
time point in total scores of ADAS-Cog, ADL and NPI 
and the results were shown in figure 2 to figure 4. For 
the  analysis,  a  covariance  model  was  used  in  the 
treatment group, and clinical time and current dosage 
were regarded as fixed effects, while baseline score 
was used as the covariate. This method might reflect a 
progressive development of AD and the data would 
not be missed at random (ie, patients who progress 
more quickly may be more likely to withdraw). The 
adverse  events  and  discontinuation  rate  were  ana-
lyzed by the Fisher exact test.  
Results 
Patient Disposition 
Eighty four patients expressed their intentions to 
participate  in  this  trial  and  were  divided  into  the 
donepezil treatment group and donepezil plus natu-
ral  hirudin  treatment  group.  The  results  of  the  chi 
square  test  and  student’s  t  test  between  the  two 
groups  did  not  show  any  significant  difference  in 
demographic data, vascular risk factors, clinical man-
ifestations  and  neuropsychological  measurements. 
The  general  characteristics  of  the  two  groups  were 
shown  in  Table  1.  All  the  participants  from  two 
groups  were  also  administered  the  following  con-
comitant medications (donepezil plus Hirudin vs sin-
gle  donepezil  treatment):  benzodiazepine  agents 
(36.4%  vs  34.8%),  antidepressants  (33.4%  vs  28.4%), 
anti hypertensive agents (27.8% vs 30.2%), serum li-
pid-reducing  agents  (20.3%  vs  26.5%).  Statistical 
analysis showed no significant difference was present 
(P>0.05), which meant there were no group effect in 
these  most  common  concomitant  medications.  50% 
patients in the combined treatment and 39% patients 
in the single donepezil treatment did not complete the 
study  due  to  the  following  reasons:  adverse  events 
(21.4%), requests of the patients or career requirement 
(9.5%), admission to nursing at home (4.8%), loss in 
follow-up and other causes (8.3%). No group differ-
ences were found in the reasons led to discontinuation 
(table 2). 
Table 1. The characteristics of the patient and the statistical analysis of the results. 
  Donepezil  Donepezil plus Hirudin  Statistic values 
Male/female  17/25  20/22  x2=0.44; P=0.51 
Age (mean±SD)  73.80 ± 8.17  71.26±10.25  t=1.26; P=0.21 
Education (mean±SD)  9.14±2.73  8.89±2.58  t=0.43; P=0.67 
Cardiovascular disease (%)  23.8  26.2  x2=0.06; P=0.80 
Hypertension (%)  38.1  31.0  x2=0.47; P=0.49 
Smoking (%)  21.4  26.2  x2=0.26; P=0.61 
Diabetes (%)  19.0  28.6  x2=1.05; P=0.31 
Hypercholesterolemia (%)  33.3  45.2  x2=1.25; P=0.26 
brain atrophy and/or mild white matter hyperintensity (%)  90.5  92.9  x2=0.16; P=0.69 
MMSE score (mean±SD)  20.4 ± 5.24  19.2 ± 5.11  t=1.06; P=0.29 
ADAS-Cog score (mean±SD)  23.9 ± 9.7  21.5 ± 8.8  t=1.19; P=0.24 
ADL score (mean±SD)  30.5±10.1  33.2±11.4  t=1.15; P=0.25 
NPI score (mean±SD)  28.4±8.6  31.3±9.1  t=1.50; P=0.14 
Duration of AD (year) (mean±SD)  3.43 ± 1.08  3.84 ± 1.11  t=1.72; P=0.09 
Comorbidities (%)  52.4   64.3  x2=1.22; P=0.27 











Adverse events  8(19.0)  10(23.8) 
Reqest of patient or carer  3(7.1)  5(11.9) 
Access to nursing home  2(5.8)  2(4.8) 
Lost to follow up and other 
causes 
3(7.1)  4(9.5) 




The ADAS-Cog scores declined at the beginning 
of the treatment but increased finally in both groups. 
This meant more impairment in the cognition of the 
patients  occurred  after  the  treatments.  The  patients 
who  received  donepezil  plus  Maixuekang  demon-
strated significant decrease in ADAS-Cog scores and 
increase in ADL scores. Compared to the donepezil 
treatment group, the ADAS-Cog scores in the com-
bined  group  had  an  obvious  decrease  (P<0.05,  uni-
variate  Student's  t  test)  and  the  patients  displayed 
much better in cognition since the 8th week. This re-
sult indicated the potency of Maixuekang in delaying 
the  cognitive  decline  in  the  patients  with  AD  as 
treated with  donepezil simultaneously (Fig. 1).  The 
ADL scores significantly improved in donepezil plus 
Maixuekang treatment group from the third evalua-
tion time point to the end of the study as compared 
with  unique  donepezil  treatment  (P<0.05,  Fig.  2). 
BPSD as evaluated by the change of NPI score also 
improved  after  the  treatment,  but  no  statistical  dif-
ference  was  found  between  the  two  groups  in  NPI 
scores (P>0.05, Fig. 3). In order to further elucidate the 
benefit of Maixuekang, subjects who participated in 
the  Maixuekang  treatment  group  were  continually 
divided  into  the  group  with  vascular  risk  factors 
(VRF)  and  the  group  without  VRF.  The  cognition, 
daily  behaviors  and  neuropsychological  symptoms 
were compared between the two groups (Fig. 4). Sta-
tistical  difference  was  present  in  ADAS-Cog,  ADL 
and  NPI  scores  from  the  4th  week  to  the  end.  The 
cognition, daily function and behavioral and psycho-
logical  symptoms  were  aggravated  as  Maixuekang 
was removed, which further proved the potency of 
Maixuekang in improving the treatment of AD and 
delaying its progress.  
Safety 
The  most  common  treatment-related  adverse 
events in this study were nausea, vomiting, headache, 
anorexia,  abnormal  dreams,  diarrhea,  infection,  hy-
pertension,  bradycardia,  accidental  injury,  hemor-
rhage and hypersensitiveness (Table  3). Ten partici-
pants in the donepezil plus Hirudin group and eight 
subjects  in  the  single  donepezil  group  experienced 
mild to moderate some of the adverse events. No se-
rious adverse events or deaths were occurred during 
the study. The statistical results about the laboratory 
and auxiliary examination did not show any signifi-
cance difference. The discontinuation rate due to the 
adverse events in patients treated with donepezil plus 
Hirudin (23.8%) was similar to that in the donepezil 
group (19.0%). Although the patients in the combin-
ing treatment group experienced higher rate of hem-
orrhage  than  the  patients  in  the  donepezil  group 
(19.1% vs 3.3%), no statistical significance was present 
(P=0.08). 
 
Table 3. The comparison (Fisher’ Exact Test) of the fre-
quency of adverse events in two groups (%). 
  Donepezil  Donepezil plus Hirudin P values 
Total adverse events 30 (71.4)  38(90.5)  0.17 
Hypersensitiveness  1 (2.4)  3 (7.1)  0.24 
Hemorrhage  1 (2.4)  5 (11.9)  0.08 
Bradycardia  2 (4.8)  1 (2.4)  0.56 
Anorexia  2 (4.8)  2 (4.8)  1.00 
Hypertension  2 (4.8)  2 (4.8)  0.64 
Infection  3 (7.1)  3 (7.1)  0.67 
Abnormal dreams  2 (4.8)  2 (4.8)  0.64 
Headache  2 (4.8)  3 (7.1)  1.00 
Vomiting  3 (7.1)  3 (7.1)  0.67 
Accidental injury  3 (7.1)  4 (9.5)  1.00 
Nausea  4 (9.5)  4 (9.5)  0.70 
Diarrhea  5 (11.9)  6 (14.3)  1.00 
 
 





Figure 1. The change of the total scores of ADAS-Cog in two groups during the treatment. Data are shown as the means and SD. on the 
study session for intention-to-treat patients. *: P<0.05 between the Donepezil treatment and the Donepezil plus Maixuekang treatment. 
#P<0.05, comparison between the time point before and after the removal of Maixuekang. 
 
 
Figure 2. The total score change of ADL total score in two groups during the treatment. Data are shown as the means and SD. *: P<0.05, 
the comparison between the two treatment groups. 
 
 





Figure 4. The comparisons of patients with vascular risk factors (VRF and without VRF in the donepezil plus Maixuekang treatment 
group). The changes of the total scores of ADAS-Cog, ADL and NPI are shown in chart A, B, and C. Data are shown as the means and SD. 
*P<0.05, the comparison between the patients with and without VRF; #P<0.05, the comparison between the time point before and after 
the removal of Maixuekang. 
 
Discussion 
AD is a progressive neurodegenerative disease 
characterized by the loss of cholinergic neurons in the 
nucleus basalis of Meynert, which is the basement of 
the cholinergic hypothesis and results in the subse-
quent  development  of  acetylcholinesterase  (AChE) 
inhibitors in AD treatment  [9]. AChE inhibitors are 
used to treat the patients with mild to moderate AD 
[10]. Since Donepezil can upregulate AChE activities 
significantly and increase the protein level of CSF in 
the patients with AD [11], it has been widely used in 
the symptomatic treatments of AD [12]. Many clinical 
trials have demonstrated that donepezil improves the 
patients’ cognition and some of the BPSD. These im-
provements of the patients can also reduce caregivers' 
burden [13]. In this research, after patients with mild 
to  moderate  AD  took  donepezil  5-10  mg/d  for  20 
weeks, marked improvements were found in the daily 
activities, abnormal behaviors and psychiatric symp-
toms. Although the cognition of the patients was im-
proved shortly at the beginning, it finally inevitably 
declined. Since no way can stop the progression of AD 
at the moment [14], the treatments mainly focus on 
the improvement or stabilization of cognitive, func-
tional and/or behavioral symptoms of the patients. In 
some cases stabilization based on reducing the wors-
ening speed may be an ideal treatment outcome [15]. 
In the study, all the evaluation methods did not in-
clude  the  natural  progression  of  AD  after  patients 
were treated by donepezil. This may be a reason why 
no  significant  enhancement  of  cognition  is  present. 
Maybe a larger dose of donepezil instead of a stand-
ard dose can give better treatment. Doses of 15 and 20 
mg/day  of  donepezil  have  been  used  in  clinic  and 
appeared  safe  and  well  tolerated  [16].  A  recent  re-
search reported that a high-dose of donepezil (23 mg 
once  daily)  brought  about  greater  benefits  than  a 
standard-dose  donepezil  (10  mg  once  daily)  in  pa-
tients with moderate to severe AD, but its use was 
also associated with high rate of withdrawal (30.2% to 
17.9%) for 24 weeks [17].  
In the study, the cognition and daily activities of 
the  patients  were  improved  obviously  after 
Maixuekang was jointly used to the donepezil-treated 
patients.  To  further  analyze  the  efficacy  of 
Maixuekang, a comparison was performed between 
those  with  VRF  and  those  without  VRF.  Results 
showed that the cognition, daily activities and psy-
chiatric  symptoms  were  improved  in  patients  with 
VRF. In the brain of Alzheimer's patients, the cholin-
ergic neurons innervating the hippocampus and cer-
ebral  cortex  degenerate  before  the  accumulation  of 
beta-amyloid protein. Donepezil has been testified to 
protect  the  cholinergic  neurons  from  the  neuro-
degeneration in olfactory bulbectomy mice [18]. This 
probably  causes  the  improvement  of  the  cerebral 
blood flow and the induction of neurogenesis in the 
hippocampus. Some researchers have already found 
that at the early stage of dementia a combination of 
the Abeta oligomers and cerebral ischemia may result 
in  the  cholinergic  synapse  dysfunction  and  induce 
memory impairment by cholinergic synapse dysfunc-




in AD patients. This change may be enhanced with 
synaptic  upregulation  after  a  long-term  donepezil 
treatment [20]. It is reported that the cerebral blood 
flow  in  the  temporal,  parietal,  and  posterior  lobes 
improves  significantly  after  6  months  of  the 
Donepezil treatment (5 mg/day) [21]. 
Hirudin  is  a  specific  thrombin  inhibitor.  This 
single-chain  polypeptide  is  composed  of  65  amino 
acid  residues  and  capable  to  bind  thrombin  with 
formation of 1 to 1 non-reversible covalent complexes. 
Preclinical  experiments  indicate  that  it  can  inhibit 
thrombosis, decrease the platelet adhesion, reduce the 
concentration  of  serum  cholesterol  and  serum  tri-
glyceride and improve the cerebral microcirculation. 
In our study, the improvement of the cognition, daily 
function and BPSD of the patients in the combined 
treated  group  may  be  due  to  the  improvement  of 
cerebral circulation, reduce of platelet aggregation.  
The basic characteristics of patients and the fea-
tures of the disease ensure the accuracy of the results 
in this research, for the pharmacotherapy and diag-
nosis, demographics, medication status, psychometric 
data and selected clinical and MRI variables may in-
fluence the progresses of AD [22]. Since the severity of 
the  cognitive  and  functional  decline  determines  the 
progression of AD from moderate to severe [23], the 
neuropsychological  assessments  measured  by 
ADAS-Cog,  ADL  and  NPI  mainly  reflect  this  pro-
gress.  Of  course,  as  these  assessments  have  certain 
limitations, they can only contain a certain degree of 
intelligence  dimensions  and  represent  some  of  the 
superior brain function.  
It  is  critical  for  AD  patients  to  adhere  to  the 
medicine  treatment.  Unfortunately,  the  medication 
adherence in these patients is difficult. A big sample 
survey reported only 58% of patients were adherent to 
oral AD medications during the 1-year follow-up pe-
riod [24]. Once-daily donepezil treatment is a good 
administration choice for Alzheimer's disease because 
donepezil can slow the disease progression and im-
prove or stabilize the life quality [25]. However, it is 
reported that the 1-year persistence rate of donepezil 
is only 46% [26]. In this research, the 20-week dropout 
rate in the donepezil treatment group is 39%. Possible 
more patients will drop out with time going on and 
the rates finally gets close to 46%. 50% patients in the 
donepezil and Maixuekang treatment group discon-
tinue the treatment. This is mainly due to the adverse 
events and the requirement of the patients and care-
givers. The manifestations and frequency of adverse 
events induced by donepezil in our patients is similar 
to  those  reported  before  [27].  The  nature  of 
Maixuekang and its pharmacological effects theoreti-
cally determine the high risks of bleeding and allergy, 
but no statistical difference is present in the frequency 
of  hemorrhage  (11.9%  vs  2.4%)  and  hypersensitive-
ness  (7.1%  vs  2.4%)  between  the  two  groups.  This 
means  that  Maixuekang  can  be  safely  used  in  the 
treatment  of  AD.  The  most  common  reason  apart 
from the requirement due to the adverse event for the 
patients and caregivers who refuse the follow up is 
the  economic  load,  such  as  worry  about  high  drug 
prices  (7.1%)  and  lack  of  medical  insurance  (3.6%). 
There were no significant differences between the two 
therapeutic groups (P>0.05). Therefore, improving the 
patients’  economic  situation  in  the  future  possible 
better the AD treatment.  
However,  some  limitations  are  still  present  in 
this  study.  First,  these  results  may  partly  reflect  a 
normal  clinical  treatment,  but  assessors  were 
un-blinded to the time-point of visit. Second, ‘ceiling 
effects’ are present, comparing the smaller effect sizes 
in a limited number of subjects with the broadly de-
fined inclusion criteria for cognitive  and behavioral 
dysfunction. Third, the same instruments are repeat-
edly used in the interviews and the participants are 
susceptible  to  the  assessment.  A  better  rigorous  re-
search with more patients needs to be performed in 
the future. 
In conclusion, our results show that the symp-
toms of the AD patients in the donepezil plus natural 
hirudin  treatment  group  than  only  treated  with 
donepezil  in  mild-to-moderate  Alzheimer's  disease 
and the formula was safe. 
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